在ER/PR+HER2-乳腺瘤中,内分泌治疗耐药性的基因组特征
Arnab Ghosh1,2, Rohan Chaubal3, Chitrarpita Das1
1Biotechnology Research and Innovation Council-National Institute of Biomedical Genomics (BRIC-NIBMG), Kalyani, India.
Communications biology
|February 10, 2025
概括
基因组分析揭示了三基因特征 (PIK3CA-ESR1-TP53) 和受损的DNA修复途径与雌激素受体阳性,HER2-阴性乳腺癌中的内分泌治疗抵抗有关.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 雌激素受体/孕激素受体阳性,HER2阴性 (ER/PR+HER2-) 乳腺瘤是最常见的亚型.
- 内分泌疗法是有效的,但耐药性和复发仍然是重大挑战,影响患者的生存.
- 在ER/PR+HER2-乳腺癌中内分泌疗法耐药性的基因组基础尚未完全理解.
研究的目的:
- 研究ER/PR+HER2-乳腺癌内分泌治疗耐药性的基因组基础.
- 为了比较来自耐药和敏感患者队列的全基因组测序数据.
- 识别与治疗失败和疾病复发相关的基因组标记物.
主要方法:
- 瘤和正常组织样本的全基因组测序 (WGS).
- 从内分泌疗法耐药和敏感的ER/PR+HER2-乳腺癌患者的WGS数据进行比较分析.
- 识别与耐药性相关的基因组特征和途径改变.
主要成果:
- 发现了一个显著的三基因抗药特征 (PIK3CA-ESR1-TP53).
- 缺陷的DNA双链断裂修复和同源重组途径与耐药性有关.
- 基因组不稳定性增加,包括副本数量变化和结构变异,明显的内分泌治疗耐药性.
结论:
- 基因组景观分析可以预测ER/PR+HER2-乳腺瘤的内分泌治疗耐药性.
- 研究结果表明,对于内分泌疗法耐药性乳腺癌,PARP抑制剂的重新用途有可能存在.
- 了解抵抗机制可以指导治疗策略并改善患者的治疗结果.
更多相关视频
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K


